



ATCOR INVITED TO PRESENT AT RODMAN & RENSHAW 9TH ANNUAL HEALTHCARE CONFERENCE

Sydney, Australia and Lisle, IL – October 22, 2007 – AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which non-invasively measures central blood pressures, today announced that AtCor Medical has accepted an invitation to present at the Rodman & Renshaw 9th Annual Global Healthcare Conference, on November 5-7, in New York City.

The Rodman & Renshaw Global Healthcare Conference is a premier event of the United States' life sciences calendar, attracting over 2,000 institutional investors, venture capitalists, industry CEOs and medical and scientific experts annually. AtCor Medical management will be available for meetings in New York on November 6-7.

Duncan Ross, AtCor Medical's Chief Executive Officer will give a presentation on November 7 at 10:50 a.m. ET about AtCor Medical's patented and FDA-cleared SphygmoCor[®] technology, which provides noninvasive assessment of central blood pressure and indices of arterial stiffness. The presentation will be followed by a question and answer session and a live webcast may be accessed at the Company's website, www.atcormedical.com, or at <http://wsw.com/webcast/rsshq12/acg.au>.

A replay of the presentation will be archived for 90 days after the conference, at the same locations. For more information about the Rodman & Renshaw 9th Annual Healthcare Conference, please visit Rodman & Renshaw's website at www.rodmanandrenshaw.com.

Major independent clinical studies using SphygmoCor[®] have shown that central pressure is a superior predictor of cardiovascular events which may reveal important drug effects that cannot be detected with traditional cuff blood pressure measurements.

Nine of the top ten leading hospitals in the *US News & World Report's* 2007 edition of "America's Best Hospitals" (published October 16, 2007 at <http://health.usnews.com/usnews/health/best-hospitals/honorroll.htm>), have adopted SphygmoCor[®] non-invasive central blood pressure measurement. In July, AtCor Medical announced that it had signed agreements with three leading international pharmaceutical companies to supply SphygmoCor[®] systems and clinical trial support services for new and ongoing drug trials in Europe and the United States.

Heart disease is the leading cause of death in the U.S. According to the American Heart Association, two of three men and one of two women in the U.S. will develop heart disease in their lifetime. Heart diseases will cost Americans an estimated \$432 billion in medical expenses and lost productivity in 2007, making it the most costly disease.

AtCor's SphygmoCor[®] system is the only FDA-cleared, non-invasive method to measure central pressures. Central blood pressure comprises the pressure exerted by the heart's contraction, plus the added pressure, which is reflected back at the heart during that heart-beat. This combined pressure, the pressure the heart pumps against, is increased by arterial stiffening and can be reduced with lifestyle changes and drug therapies.

About AtCor Medical

AtCor Medical develops and markets products for the early detection and management of cardiovascular disease. More than 1,000 SphygmoCor systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 799 8221

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au